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Abstract
Background: Several measurements are often used in daily clinical practice in the assessment of Ankylosing
Spondylitis (AS) patients. The Assessment in SpondyloArthiritis International Society (ASAS) recommend in its core
set: chest expansion modified Schöber test, Occiput to wall distance, lateral lumbar flexion, cervical rotation and
The Bath Ankylosing Spondylitis Metrology Index (BASMI). BASMI also includes five measurements, some of them
recommended by ASAS. Three versions of BASMI have been published with different scales and intervals for each
component of the index. Though studies about reliability of these measurements are needed. The aim of this study
was to analyze inter-rater reliability of recommended spinal mobility measures in AS.
Methods: We examined reproducibility of spinal mobility measurements on 33 AS patients performed by two
experienced rheumatologists in the same day. Descriptive statistics, Intraclass Correlation Coefficients (ICC), and
Smallest Detectable Difference (SDD) using the Bland-Altman criteria were obtained for all the measurements.
Results: Chest expansion showed the lowest value of ICC (0.66) and occiput-wall the highest (0.97). SDD was 2.43
units for BASMI2 and 1.27 units for BASMI10.
Conclusions: Reliability according to ICC was moderate to high in all measurements. BASMI10, instead BASMI2, must
be used: measurements used to calculate are the same but there is better reliability. Inter-rater variation, expressed
as SDD, must be taken in account: smaller improvements do not demonstrate the efficacy of treatment because
they can be due to experimental error and not to the treatment itself.
Keywords: Ankylosing spondylitis, Reliability, Reproducibility, Smallest detectable difference, BASMI
Abbreviations: AS, Ankylosing spondylitis; ASAS, Assessment of Spondylo Arthritis International Society;
BASMI, Bath ankylosing spondylitis metrology index; CV, Coefficient of variation; ICC, Intraclass correlation coefficient;
OMERACT, Outcome measures in rheumatoid arthritis clinical trials; SDD, Small detectable difference;
SpA, Spondyloarthropaties
Background
Ankylosing Spondylitis (AS) is a subtype of Spondyloar-
thropaties (SpA), which affects mainly the spine. Spinal
mobility impairment in AS patients is caused both by in-
flammation and structural damage of the spine [1, 2].
Assessment of the reduction in spinal mobility is funda-
mental to evaluate disease stage and disease evolution in
the patients [3]. Several studies showed that the evolu-
tion of the disease is highly correlated with the reduction
in spinal mobility [4, 5]. Several measurements were de-
fined to assess spinal mobility in AS, among them due
to their greater acceptance are those recommended by
ASAS (The Assessment of SpondyloArthritis inter-
national Society) group its comprise different spinal mo-
bility measures in a core set [6]: chest expansion,
modified Schöber test, occiput to wall distance, lateral
lumbar flexion or BASMI (Bath Ankylosing Spondylitis
Metrology Index).
BASMI was defined in 1994 by Jenkinson et al. [7] and
includes five measurements: cervical rotation, tragus to wall
distance, lateral lumbar flexion, modified Schöber, and
intermalleolar distance. Each one of these measurements is
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classified in three levels of severity (0 =Mild, 1 =Moderate,
2 = Severe) according to values defined for each interval.
Summing up the results obtained for the five measure-
ments, an index between zero and ten is obtained. This
index was validated in several studies showing good reliabil-
ity and correlation with radiological measures [8]. BASMI
is used as a tool for patient’s classification and to analyze
the sensitivity to change of different treatments. In 1995, a
second definition of BASMI was published by Jones et al.
[9], using the same measurements, but establishing ten in-
tervals in each measurement. Averaging individual scores,
an index between zero and ten is obtained. This new scale
gave a greater precision of the evaluation obtained by each
measurement (multiples of 0.2 units instead multiples of 1
unit). More recently, Van deer Heidje et al. [10] proposed a
BASMI version in which a linear function was applied for
calculate each index component. According to the authors,
this definition of BASMI, whose results were very similar to
Jenkinson’s version, provides better results of the reliability
and sensitivity to change. Thus, there are three versions of
BASMI: original BASMI2, BASMI10 and linear BASMILIN.
Another metrological indexes and new measurement
protocols have been defined [11, 12] but the most used
spinal mobility measurements are the ones recommend
by ASAS.
BASMI is not always performed in daily clinical prac-
tice, due to the difficulty to obtain certain measurements
(cervical rotation with a goniometer, intermalleolar dis-
tance needs more physical space). Although BASMI2 is
used more than BASMI10, the latter has higher accuracy,
for the same measurements. Although in most publica-
tions BASMI2 is used, it is often not clear to the readers
which of the three definitions were applied.
In this study, we analyzed inter-observer variability of
different spinal mobility including ASAS core set and
BASMI, with its three different versions. Our aim was to
obtain reliability of the spinal measurements and to de-
termine the smallest detectable difference, which must
be considered in order to demonstrate the efficacy of the
treatment assessed with spinal measurements.
Methods
Patients
We included 33 consecutive patients from daily clinical
practice from Rheumatology Department of University
Hospital Reina Sofia, Córdoba. Inclusion criteria were:
patients diagnosed with AS according to the modified
New York criteria, having at least 5 years of disease dur-
ation and with ages between 18 and 80 years. They were
all informed and consented to participate in the study,
who was approved by the Reina Sofia Hospital Research
Ethics Committee. Exclusion criteria were: pregnant,
spinal surgery and scoliosis.
Only four of them were female. These patients had dif-
ferent level of mobility impairment varying from 0.94 to
8.78 (average value 4.75) according to BASMI10. The
medium age was 50.35 years, and disease evolution was
24.61 years.
Spinal measurements were performed by two experi-
enced rheumatologists. Two assessments in independent
and isolated way were performed in the same day by
each rheumatologist. All tests were done in the evening
during three months period.
Variables
There are more than 20 measurements used for AS
assessment. Mobility measures were reviewed by Sieper
et al. [13]. This review makes a precise description of
the most used metrology measures (including all the
measures analyzed in our study) and how to calcu-
late them.
ASAS recommends chest expansion, modified Schöber
and occiput to wall distance and lateral lumbar flexion
or BASMI. BASMI includes: cervical rotation, tragus to
wall distance, lateral lumbar flexion, modified Schöber
and intermalleolar distance. Three ranges of BASMI
were considered: BASMI2, BASMI10, BASMILIN. As, the
last two are very similar we will use only BASMI2 and
BASMI10. Finger to floor distance was also included be-
cause it is a measure often used in studies. In total, we
analyzed eight measurements and two indexes.
Statistics
We used intraclass correlation coefficient (ICC) for stat-
istical analysis of inter-observer reliability. A value upper
to 0.6 indicates good reliability, a value superior to 0.8
indicates a very good reliability and upper to 0.9 repre-
sents an excellent reliability. Determination of the smal-
lest detectable difference was made using Bland-Altman
method [14]. According to this method, 95 % limit of
confidence is defined as the difference measured be-
tween observers for each measurement +/− 1.96 the
standard deviation. Assuming that the differences are
normally distributed the mean difference must be near
zero. We used SPSS® 14.0 (SPSS International BV,
Chicago, USA) and Medcalc® 11.3.6 (Medcalc Software
bvba, Mariakerke, Belgium) to interpret the results.
Results
Results obtained by both observers for the analyzed pa-
rameters are shown in Table 1. High variability was ob-
served in chest expansion and Schöber test. Values over
one unit in BASMI10 and two units in BASMI2 indicated
high values of SDD.
Table 2 shows inter-observer reliability according to
ICC. Results of reliability compared with already pub-
lished studies are also included. Although ICC values are
Calvo-Gutiérrez et al. BMC Musculoskeletal Disorders  (2016) 17:382 Page 2 of 6
high, for a good instrument for individual decision-
making, these values must be over 0.9. Not all measure-
ments fulfill this condition.
Correlations between measures (Pearson) are showed
in Table 3. High correlation values appeared in BASMI
indexes with the rest of measures.
Figure 1 shows Bland-Altman plots comparing the
scores of the two BASMI definitions obtained for both
observers.
Discussion
The main conclusion of our study is that inter-observer
variability expressed as SDD must be kept in mind in
order to justify patient improvement for short-term
follow-up treatments. Every measurement included in
ASAS core set and BASMI was analyzed.
Davis et al. [15] in a bibliographical review, studied
the different spinal mobility measurements used to
assess loss of mobility in AS, including BASMI, ana-
lyzing their validity applying the OMERACT filter
(Outcome Measures in Rheumatoid Arthritis Clinical
Trials). Although Davis shown good results, some
studies show certain problems of reliability, accuracy
and variability of these mobility measurements.
Auleley et al. [16] calculated the smallest detectable
difference (SDD) of several measurements used in AS
assessment (chest expansion, occiput to wall distance
and modified Schöber). This was the first study pro-
viding SDD as outcome measurement in AS based on
Bland-Altman’s 95 % limits of agreement method
[14]. The SDD was relatively high and, although ICCs
were high, it appeared to be poorly reliable judged by
Table 1 Results obtained by observers and differences between measurements
Measurement Observer 1 Observer 2 Difference C.V. S.D.D.
































































Results of observers and difference are expressed as mean (SD) [Min-Max]
CV coefficient of variation: SD of difference divided by mean value in %, SDD smallest detectable difference according Bland-Altman criteria
a Included in ASAS core set. b Included in BASMI
Table 2 Reliability obtained in our study and published by other authors
Measurement ICC Inter (95 % CI) Davis [15] Haywood [8] Maksym.[11] Viitanen [3]
Chest expansion a (cm) 0.659 (>0.412) 0.85 - 0.98 0.85
Modified Schöber a,b (cm) 0.756 (>0.561) 0.96 0.90 0.97 0.96
Occiput-wall a (cm) 0.967 (>0.934) 0.92 0.98 0.89
Tragus-wall b (cm) 0.962 (>0.924) 0.99 - 0.96 0.90
Finger to floor distance (cm) 0.948 (>0.893) 0.98 0.96
Lumbar side flexion a, b (cm) 0.817 (>0.651) 0.98 0.95 0.95 0.98
Intermalleolar distance b (cm) 0.944 (>0.857) 0.99 - 0.98
BASMI10 0.956 (>0.913) - -
BASMI2
a 0.894 (>0.796) 0.96 - 0.95
aIncluded in ASAS core set. bIncluded in BASMI
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SDD. Consequently, changes smaller than SDD, could
be considered as measurement error.
Different reliability results were obtained, for each
measures analyzed. Next we will review some of these
results comparing them with the obtained in the current
literature.
Chest expansion showed the worst results (CV
47.31 %, ICC 0.659, SDD 3.27 cm). Is one of the most
complicated measures to be obtained and it has special
problems to be done in women. According to Auleley
[16] ICC was 0.85 and SDD 2.4 cm. This measurement
may be useful, because the reduction of pulmonary cap-
acity in AS is well known, but the actual measure
system is not appropriate. Tzelepis et al. [17] used the
thoracoabdominal movement in breathing as outcome
parameter of the disease.
Modified Schöber is one of the mobility measures
more used. Clear correlations with radiology and symp-
toms duration has been described [3]. Reliability results
were good (CV 42,8 %, ICC 0.756, SDD 2.39 cm), higher
than chest expansion but lower than the rest of the mea-
sures. Our results were very similar with Auleley [15]
(ICC 0.60, SDD 3.3 cm).
Occiput-wall / Tragus-wall distances are related with
kyphosis seen in AS. Greater level of affectation implies
greater kyphosis. ASAS recommends occiput-wall, al-
though this parameter is difficult to measure when the
patient is only some millimeters separated from the wall.
Measuring tragus-wall is easier in this situation (BASMI
includes this measure), but this distance depends on the
size of the patient’s head. In BASMI2, values less than
15 cm are scored with 0 (no affectation). Normally the
distance tragus to occiput is about 11 cm. In this case,
there is no problem if the patient touches the wall. How-
ever, in BASMI10, the zero value for this measure is
10 cm, so the patient will be scored with 1 unit and will
be affected according this index. Some studies [18, 19]
assessed BASMI in healthy subjects and they discovered
that it is unusual for healthy individuals to score zero on
the BASMI. Both measures, obtained good reliability re-
sults (especially tragus to wall). Also they showed good
correlations with the rest of parameters. Therefore, ky-
phosis is a good indicator of the level of affectation.
Floor to finger distance is not included in ASAS core
set neither in BASMI. In spite of having a high reprodu-
cibility (ICC = 0.948), it does not correlate well with
BASMI index (r = 0.44), nor with the rest of parameters.
This fact can be due to the influence of the height of the
subject, although some studies declined it [20]. Some
studies show poor correlation with radiology for this
measure [21].
Table 3 Correlation (Pearson) between measures
CE MS OW TW FFD FL ID BASMI10 BASMI2
CE 1.000 0.435* −0.334 −0.360* 0.057 0.234 0.377 −0.448** −0.499**
MS 0.435* 1.000 −0.409* −0.370* −0.275 0.510** 0.070 −0.610** −0.667**
OW −0.334 −0.409* 1.000 0.979** 0.262 −0.676** −0.552* 0.817** 0.688**
TW −0.360* −0.370* 0.979** 1.000 0.187 −0.707** −0.572* 0.802** 0.713**
FFD 0.057 −0.275 0.262 0.187 1.000 −0.438* −0.563* 0.442* 0.316
FL 0.234 0.510** −0.676** −0.707** −0.438* 1.000 0.366 −0.800** −0.765**
ID 0.377 0.070 −0.552* −0.572* −0.563* 0.366 1.000 −0.697** −0.520*
B10 −0.448** −0.610** 0.817** 0.802** 0.442* −0.800** −0.697** 1.000 0.916**
B2 −0.449** −0.667** 0.688** 0.713** 0.316* −0.765** −0.767** 0.916** 1.000
*p < 0.05; ** p < 0.01
CE chest expansion, MS modified Schöber, OW occiput to wall distance, TW Tragus to wall distance, FFD finger to floor distance, ID intermalleolar distance
B10:BASMI10. B2:BASMI2
Fig. 1 Bland-Altman plots illustrating inter-observer variability of
assessing BASMI according BASMI2 and BASMI10
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Unlike finger to floor distance, lateral lumbar flexion
showed good correlation with the rest of measures
(Schöber, occiput and tragus to wall distance, and
BASMI, p < 0.01). ICC was good (0.817), something in-
ferior than obtained by other authors (0.95–0.98).
Intermalleolar distance measure showed excellent
values of repeatability (ICC = 0.944) and good correla-
tions with some of the analyzed parameters. It is com-
plex to measure and requires more space and time in
clinical practice, for this reason is not habitually used.
We have calculated BASMI using the two scales
previously described (BASMI2.and BASMI10). BASMI10
showed better results than BASMI2. BASMI correlated
well with almost all of the measures. Floor to finger dis-
tance did not show correlation with this index. We ob-
tained a SDD of BASMI2 of 2.43 units, while for
BASMI10 it was half the value (1.27 units). This result is
shown in Fig. 1. CV also varied from 30.47 to 13,71 %.
ICC was good in both cases (0.894 to 0.956); therefore
the variability is smaller for the second index. The pub-
lished results of variability are near to the values ob-
tained in our study.
According to Madsen [22] the SDD, in BASMI2 was of
+/− 1.4 (+/− 2 units in valuations on individual patients).
Another study performed by Martidale et al. [23] shown
that for repeat assessments of the same participant, dif-
ferences in BASMI of 1.0 or less are within bounds of
error. Therefore, an improvement below these units may
be due to the experimental error and not to the treat-
ment itself.
Some studies showed improvements of less than one
unit in BASMI2 and BASMI10 in patients treated with
biological agents [24, 25]. These values are less than the
smallest detectable difference established for BASMI and
therefore, the improvement could be due to the experi-
mental error of the measure. It is a fact that BASMI is
seldom used to evaluate the short-term effectiveness of
the treatment. Some authors prefer to use lateral side
flexion instead BASMI [26]. Braun et al. [27] indicated
that although biological treatment improves AS activity
indices, this improvement is less important with the re-
spect to spinal mobility (assessed with BASMI), but he
strengthened out that BASMI does not have much sensi-
tivity to change. Jauregui et al. [28] analyzed BASMI in a
controlled trial using pamidronated and they concluded
that responsiveness of the BASMI was poor with either
scoring system (BASMI2 and BASMI10).
To summarize, BASMI10 must be used because the mea-
sures included are the same and requires only little extra ef-
fort in its calculation. Although we obtained better results
for BASMI10, BASMI2 is still using in clinical practice.
As a limitation of our study, the results we provide for
SDD are based on a relative small number of patients and
observers but, the results are similar to other studies.
Conclusions
In order to analyze clinical significance of our results,
SDD of the different measurements must be kept in
mind when demonstrating the efficacy of treatments in
short term studies. Another possibility is to research for
advanced metrology tools with better reliability results
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